QuantumClinics develops hybrid AI + Quantum platforms to transform pharmaceutical research. Greater precision, fewer clinical failures, better therapies for patients.
To establish a national and European centre of competence and excellence for AI and quantum computing technologies oriented to the healthcare world.
To contribute to the transformation of pharmaceutical research by integrating classical AI and quantum computing into a single, modular, clinically validated platform.
Accelerating pharmaceutical discovery, genomics and intensive care medicine — enabling faster, safer and more personalised treatments through hybrid classical-quantum computing.
The current pharmaceutical development system is slow, expensive and inefficient. Classical computational methods have reached their structural limits: they cannot model with sufficient precision the quantum complexity of biological molecules.
Billions of potentially bioactive molecules remain invisible to classical screening methods.
Traditional docking and molecular dynamics simulations suffer from approximations that reduce predictive accuracy.
Genomics, proteomics and clinical data remain separate silos, preventing a holistic view of the patient and disease.
Our modular Q-Drug platform integrates classical artificial intelligence and quantum computing into an end-to-end flow for pharmaceutical discovery.
Classical AI to reduce chemical space from millions to hundreds of promising candidates, followed by high-precision quantum evaluation.
Modelling of protein folding and ligand-protein interactions with precision impossible for classical methods.
Integration of genomic, proteomic and ADMET data from a consolidated network of over 80 intensive care units and research institutions.
From molecular library to structured reports for clinical studies and patents, with interactive dashboard and GDPR/ISO27001 compliance.
"A quantum system can naturally simulate another quantum system."
Molecules and qubits both speak the language of quantum mechanics: superposition, entanglement, interference.
The state space of N qubits can exactly represent the state space of N electrons in a molecule.
N qubits implicitly encode 2^N amplitudes simultaneously — a capability unreachable with classical computing.
Quantum gates directly implement the unitary transformations that govern molecular dynamics.
Hybrid platforms to accelerate the discovery of new drugs, from screening phase to preclinical candidate, with quantum precision.
Quantum design of new antibiotics against multi-drug resistant pathogens — a global health emergency neglected by the major pharmaceutical industry.
Integration of genomic, proteomic and clinical data for personalised therapies, leveraging hybrid classical-quantum computational power.
50+ qubit cloud processors (IBM, IonQ and others) are now remotely accessible with continuously improving uptime and fidelity — making drug discovery applications realistic within the 2027-2030 window.
The Quantum Europe Strategy has already invested over €11 billion. The forthcoming European Quantum ACT will open new funding opportunities. Italy has launched its National Strategy for Quantum Technologies.
Hospitals and pharmaceutical companies require tools to analyse large volumes of clinical and experimental data. Digital health grows at rates above 18% annually. The competitive advantage window is open today.
A founding team with unique expertise at the intersection of quantum computing, AI, computational chemistry and clinical medicine.
Researchers specialised in variational algorithms and QML
Experts in hybrid classical-quantum models and deep learning
Specialists in molecular simulations and ADMET profiling
Professionals with experience in intensive care and pharmacology
Full-stack engineers with expertise in certified medical systems
Are you a pharmaceutical company, university, investor or hospital interested in collaborating? Let's talk.
Via San Michele del Carso, 39
20851 Lissone (MB), Italy
We are interested in partnerships with pharmaceutical companies, research institutions, universities and investors who share our vision of a future where quantum technology accelerates the development of life-saving therapies.